This Article Full Text Full Text (PDF) All Versions of this Article: 119/4/530    most recent CIRCULATIONAHA.108.826214v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Solomon, S. D. Search for Related Content PubMed PubMed Citation Articles by Solomon, S. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM Related Collections Hypertrophy Clinical Studies CT and MRI Related Article

(Circulation. 2009;119:530-537.)
© 2009 American Heart Association, Inc.

Hypertension

Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

Scott D. Solomon, MD; Evan Appelbaum, MD; Warren J. Manning, MD; Anil Verma, MD; Tommy Berglund, MD; Valentina Lukashevich, MD; Cheraz Cherif Papst, MS; Beverly A. Smith, RN; Björn Dahlöf, MD, PhD, for the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators

From the Brigham and Women’s Hospital, Boston, Mass (S.D.S., A.V.); Beth Israel Deaconess Medical Center, Boston, Mass (E.A., W.J.M.); Sahlgrenska University Hospital/Östra, Göteborg, Sweden (T.B., B.D.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.L., B.A.S.); and Novartis Pharma AG, Basel, Switzerland (C.C.-P.).

Correspondence to S.D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail ssolomon{at}rics.bwh.harvard.edu

Received August 19, 2008; accepted November 10, 2008.

Background— Left ventricular (LV) hypertrophy, a marker of cardiac end-organ damage, is associated with an increased risk of cardiovascular morbidity and mortality. Inhibitors of the renin-angiotensin-aldosterone system may reduce LV mass to a greater extent than other antihypertensive agents. We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV mass in hypertensive patients.

Methods and Results— We randomized 465 patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m² to receive aliskiren 300 mg, losartan 100 mg, or their combination daily for 9 months. Patients were treated to standard blood pressure targets with add-on therapy, excluding other inhibitors of the renin-angiotensin-aldosterone system and β-blockers. Patients underwent cardiovascular magnetic resonance imaging for assessment of LV mass at baseline and at study completion. The primary objective was to compare change in LV mass index from baseline to follow-up in the combination and losartan arms; the secondary objective was to determine whether aliskiren was noninferior to losartan in reducing LV mass index from baseline to follow-up. Systolic and diastolic blood pressures were reduced similarly in all treatment groups (6.5±14.9/3.8±10.1 mm Hg in the aliskiren group; 5.5±15.6/3.7±10.7 mm Hg in the losartan group; 6.6±16.6/4.6±10.5 mm Hg in the combination arm; P<0.0001 within groups, P=0.81 between groups). LV mass index was reduced significantly from baseline in all treatment groups (4.9-, 4.8-, and 5.8 g/m² reductions in the aliskiren, losartan, and combination arms, respectively; P<0.0001 for all treatment groups). The reduction in LV mass index in the combination group was not significantly different from that with losartan alone (P=0.52). Aliskiren was as effective as losartan in reducing LV mass index (P<0.0001 for noninferiority). Safety and tolerability were similar across all treatment groups.

Conclusions— Aliskiren was as effective as losartan in promoting LV mass regression. Reduction in LV mass with the combination of aliskiren plus losartan was not significantly different from that with losartan monotherapy, independent of blood pressure lowering. These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.

---

 

CLINICAL PERSPECTIVE

Related Article:

Circulation: Clinical Summaries
Circulation 2009 119: 487-488. [Extract] [Full Text]

This article has been cited by other articles:

				R. H. Fagard, H. Celis, L. Thijs, and S. Wouters Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies Hypertension, November 1, 2009; 54(5): 1084 - 1091. [Abstract] [Full Text] [PDF]

				P. S Sever, A. H Gradman, and M. Azizi Managing cardiovascular and renal risk: the potential of direct renin inhibition Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 65 - 76. [Abstract] [PDF]